




Patent Docket P1134R2C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|--|---|
| <p>In re Application of</p> <p>Avi J. Ashkenazi et al.</p> <p>Serial No.: 10/688,132</p> <p>Filed: October 17, 2003</p> <p>For: DcR3 POLYPEPTIDE, A TNFR HOMOLOG</p> | <p>Group Art Unit: to be assigned</p> <p>Examiner: to be assigned</p> <p>Confirmation No:</p> <p>Customer No: 09157</p> |
| | <p>CERTIFICATE OF EXPRESS MAILING</p> <p>Express Mail Number: EV 351 932 242 US</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450".</p> <p>March 11, 2004</p> <p></p> <p>Mona Beltran</p> |

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449 with 13 References;
3. Return postcard.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: March 11, 2004


By:



Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416



Patent Docket P1134R2C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|--|---|
| In re Application of Avi J. Ashkenazi et al. Serial No.: 10/688,132 Filed: October 17, 2003 For: DcR3 POLYPEPTIDE, A TNFR HOMOLOG | Group Art Unit: to be assigned Examiner: to be assigned Confirmation No: CUSTOMER NO: 09157 CERTIFICATE OF EXPRESS MAILING Express Mail Number: <u>EV 351 932 242 US</u> <small>I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450".</small> <u>March 11</u> , 2004 <u>Mona Beltran</u> Mona Beltran |
|--|---|

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

(X) **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

(If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.)

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of item numbers 1-2, 32-40, 148 and 221 on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 10/456,819, filed June 6, 2003 and relied upon in this application for an earlier filing date under 35 USC §120.

Serial No.: 10/688,132
Filed: October 17, 2003

Page 3

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ (X) not given

☐ given for each listed item

☐ given for only non-English language listed item(s) (Required)

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: March 11 2004

By:

Diane L. Marschang

Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416

FORM PTO-1449

MAR 15 2004

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1134R2C4

Serial No.

10/688,132

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

17 Oct 2003

Group

U.S. PATENT DOCUMENTS

| Examiner Initials | | Document Number | Date | Name | Class | Subclass | Filing Date |
|----------------------|------|-----------------|----------|------------------|-------|----------|-------------|
| | 1 | 09/006,352 | 13.01.98 | Gentz et al. | | | |
| | 2 | 09/518,931 | 03.03.00 | Gentz et al. | | | |
| | * 3 | 2002/0068064 | 06.06.02 | Shen-Chih et al. | | | |
| | * 4 | 2002/0150583 | 17.10.02 | Gentz et al. | | | |
| | * 5 | 4,179,337 | 18.12.79 | Davis et al. | | | |
| | * 6 | 4,301,144 | 17.11.81 | Iwashita et al. | | | |
| | * 7 | 4,399,216 | 16.08.83 | Axel et al. | | | |
| | * 8 | 4,496,689 | 29.01.85 | Mitra, G. | | | |
| | * 9 | 4,640,835 | 03.02.87 | Shimizu et al. | | | |
| | * 10 | 4,670,417 | 02.06.87 | Iwasaki et al. | | | |
| | * 11 | 4,676,980 | 30.06.87 | Segal et al. | | | |
| | * 12 | 4,736,866 | 12.04.88 | Leder et al. | | | |
| | * 13 | 4,791,192 | 13.12.88 | Nakagawa et al. | | | |
| | * 14 | 4,816,567 | 28.03.89 | Cabilly et al. | | | |
| | * 15 | 4,870,009 | 26.09.89 | Evans et al. | | | |
| | * 16 | 4,946,778 | 07.08.90 | Ladner et al. | | | |
| | * 17 | 5,010,182 | 23.04.91 | Brake et al. | | | |
| | * 18 | 5,364,934 | 15.11.94 | Drayna et al. | | | |
| | * 19 | 5,447,851 | 05.09.95 | Beutler et al. | | | |
| | * 20 | 5,885,800 | 23.03.99 | Emery et al. | | | |
| | * 21 | 6,599,716 | 29.07.03 | Hsu | | | |
| | * 22 | 60/035,496 | | | | | 14.01.97 |
| | * 23 | 60/035,722 | | | | | 28.01.97 |
| | * 24 | 60/037,829 | | | | | 05.02.97 |
| | * 25 | 60/079,856 | | Dou et al. | | | 30.03.98 |
| | * 26 | 60/086,074 | | Dou et al. | | | 20.05.98 |
| | * 27 | 60/099,643 | | Dou et al. | | | 09.09.98 |
| | * 28 | 60/112,577 | | Dou et al. | | | 17.12.98 |
| | * 29 | 60/112,703 | | Dou et al. | | | 18.12.98 |
| | * 30 | 60/112,933 | | Dou et al. | | | 18.12.98 |
| | * 31 | 60/113,407 | | Dou et al. | | | 22.12.98 |
| | 32 | 60/121,774 | | Gentz et al. | | | 04.03.99 |
| | 33 | 60/124,092 | | Gentz et al. | | | 12.03.99 |
| | 34 | 60/131,270 | 27.04.99 | Watanabe et al. | | | |
| | 35 | 60/131,964 | 30.04.99 | Gentz et al. | | | |
| | 36 | 60/146,371 | 02.08.99 | R. Gentz et al. | | | |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | |
|--|--|---|--|-------------------------------|--------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1134R2C4 | Serial No. 10/688,132 |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Ashkenazi et al. | |
| | | | | Filing Date 17 Oct 2003 | Group |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|-----------------|------------|----------|--------------|----------|-------------|--|
| Examiner Initials | Document Number | Date | Name | Class | Subclass | Filing Date | |
| | 37 | 60/168,235 | 01.12.99 | Gentz et al. | | | |
| | 38 | 60/227,598 | 25.08.00 | Gentz et al. | | | |
| | 39 | 60/252,131 | 21.11.00 | Gentz et al. | | | |
| | 40 | 60/303,224 | 06.07.01 | Gentz et al. | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------|--------------|----------|---------------------------------|----------|-----------------------|--|
| Examiner Initials | Document Number | Date | Country | Class | Subclass | Translation Yes No | |
| | * 41 | 0,003,089 A1 | 25.07.79 | EPO (ENGLISH ABSTRACT ATTACHED) | | | |
| | * 42 | 036,776 | 30.09.81 | EPO | | | |
| | * 43 | 073,657 | 09.03.83 | EPO | | | |
| | * 44 | 117,058 A2 | 29.08.84 | EPO | | | |
| | * 45 | 117,060 A2 | 29.08.84 | EPO | | | |
| | * 46 | 307,247 | 15.03.89 | EPO | | | |
| | * 47 | 362,179 A2 | 04.04.90 | EPO | | | |
| | * 48 | 417,563 | 20.03.91 | EPO (ENGLISH ABSTRACT ATTACHED) | | | |
| | * 49 | 861,850 | 02.09.98 | EPO | | | |
| | * 50 | 19,809,978 | 16.09.99 | GERMANY | | | |
| | * 51 | WO 00/32221 | 08.06.00 | PCT | | | |
| | * 52 | WO 00/52028 | 08.09.00 | PCT | | | |
| | * 53 | WO 00/53758 | 14.09.00 | PCT | | | |
| | * 54 | WO 00/58465 | 05.10.00 | PCT | | | |
| | * 55 | WO 00/58466 | 05.10.00 | PCT | | | |
| | * 56 | WO 87/05330 | 11.09.87 | PCT | | | |
| | * 57 | WO 89/05859 | 29.06.89 | PCT | | | |
| | * 58 | WO 90/13646 | 15.11.90 | PCT (ENGLISH ABSTRACT ATTACHED) | | | |
| | * 59 | WO 91/00360 | 10.01.91 | PCT | | | |
| | * 60 | WO 92/20373 | 26.11.92 | PCT | | | |
| | * 61 | WO 93/08829 | 13.05.93 | PCT | | | |
| | * 62 | WO 97/23614 | 03.07.97 | PCT | | | |
| | * 63 | WO 97/25428 | 17.07.97 | PCT | | | |
| | * 64 | WO 98/30694 | 16.07.98 | PCT | | | |
| | * 65 | WO 98/32856 | 30.07.98 | PCT | | | |
| | * 66 | WO 99/04001 | 28.01.99 | PCT | | | |
| | * 67 | WO 99/07738 | 18.02.99 | PCT | | | |
| | * 68 | WO 99/11791 | 11.03.99 | PCT | | | |
| | * 69 | WO 99/14330 | 25.03.99 | PCT | | | |

| | |
|----------|-----------------|
| Examiner | Date Considered |
|----------|-----------------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | | | | |
|--|------|---|----------|-------------------------------|--------------------------|----------|----------------------------|--|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1134R2C4 | Serial No. 10/688,132 | | | |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Ashkenazi et al. | | | | |
| | | | | Filing Date 17 Oct 2003 | Group | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | |
| Examiner Initials | | Document Number | Date | Country | Class | Subclass | Translation Yes No | |
| | * 70 | WO 99/26977 | 03.06.99 | PCT | | | | |
| | * 71 | WO 99/31128 | 24.06.99 | PCT | | | | |
| | * 72 | WO 99/50413 | 10.07.99 | PCT | | | | |
| | * 73 | 2,211,504 | 05.07.89 | UNITED KINGDOM | | | | |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | | |
| | * 74 | Altschul and Gish, "Local Alignment Statistics" <u>Methods in Enzymology</u> 266:460-480 (1996) | | | | | | |
| | * 75 | Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-Induced Death of Developing T Cells" <u>Symposium on Programmed Cell Death</u> (Abstract No. 10), Cold Spring Harbor Laboratory (1995) | | | | | | |
| | * 76 | Anderson et al., "A Homologue of the TNF Receptor and Its Ligand Enhance T-Cell Growth and Dendritic-Cell Function." <u>Nature</u> , 390(6656):175-179 (Nov 13, 1997) | | | | | | |
| | * 77 | Anderson, W.F., "Human Gene Therapy." <u>Science</u> , 256(5058):808-813 (May 8, 1992) | | | | | | |
| | * 78 | Aplin and Wriston, "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids" <u>CRC Crit. Rev. Biochem.</u> 10(4):259-306 (1981) | | | | | | |
| | * 79 | Arase et al., "Fas-mediated cytotoxicity by freshly isolated natural killer cells" <u>Journal of Experimental Medicine</u> 181(3):1235-1238 (Mar 1, 1995) | | | | | | |
| | * 80 | Ashkenazi and Chamow, "Immunoadhesins: An Alternative to Human Monoclonal Antibodies" <u>Methods: A Companion to Methods in Enzymology</u> 8:104-115 (1995) | | | | | | |
| | * 81 | Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991) | | | | | | |
| | * 82 | Bai et al., "Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster" <u>Proc. Natl. Acad. Sci.</u> 97:1230-1235 (2000) | | | | | | |
| | * 83 | Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993) | | | | | | |
| | * 84 | Bodmer et al., "TRAMP, A Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)." <u>Immunity</u> , 6:79-88 (1997) | | | | | | |
| | * 85 | Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991) | | | | | | |
| | * 86 | Bolivar et al., "Construction and Characterization of New Cloning Vehicles. II. A Multipurpose Cloning System" <u>Gene</u> 2:95-113 (1977) | | | | | | |
| | * 87 | Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987) | | | | | | |
| | * 88 | Brockhaus et al., "Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies." <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990) | | | | | | |
| | * 89 | Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987) | | | | | | |
| Examiner | | | | Date Considered | | | | |

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | |
|---|---|---|--|-------------------------------|--------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1134R2C4 | Serial No. 10/688,132 |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Ashkenazi et al. | |
| | | | | Filing Date 17 Oct 2003 | Group |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| * 90 | Brojatsch et al., "CAR1, A TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis." <u>Cell</u> 87:845-855 (1996) | | | | |
| * 91 | Carter et al., "Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (June 25, 1986) | | | | |
| * 92 | Chang et al., "Phenotypic Expression in E. coli of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978) | | | | |
| * 93 | <u>Chemotherapy Service Ed.</u> , M.C. Perry, Baltimore, MD:Williams & Wilkins (1992) | | | | |
| * 94 | Chicheportiche et al., "TWEAK, A New Secreted Ligand in the Tumor Necrosis Factor Family that Weakly Induces Apoptosis." <u>Journal of Biological Chemistry</u> 272(51):32401-32410 (1997) | | | | |
| * 95 | Chinnaiyan et al., "Signal Transduction by DR3, A Death Domain-Containing Receptor Related to TNFR-1 and CD95." <u>Science</u> 274:990-992 (1996) | | | | |
| * 96 | Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-12 (1976) | | | | |
| * 97 | Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York:Alan R. Liss, Inc. pps. 77-96 (1985) | | | | |
| * 98 | Coligan et al. <u>Current Protocols in Immunology</u> , New York:John Wiley & Sons, Inc. (1994) | | | | |
| * 99 | Creighton,, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u> , San Francisco:W.H. Freeman & Co. pps. 79-86 (1983) | | | | |
| *100 | David and Reisfeld., "Protein Iodination with Solid State Lactoperoxidase." <u>Biochemistry</u> 13(5):1014-1021 (1974) | | | | |
| *101 | de Boer et al., "The tac Promoter: A functional Hybrid Derived From the trp and lac Promoters" <u>Proc. Natl. Acad. Sci. USA</u> 80:21-25 (1983) | | | | |
| *102 | Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon-γ" <u>European Journal of Immunology</u> 17:689-693 (1987) | | | | |
| *103 | Deutscher, M., "Rethinking your purification procedure" <u>Methods in Enzymology</u> 182:779-780 (1990) | | | | |
| *104 | Dhein et al., "Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)" <u>Nature</u> 373(6513):438-441 (Feb 2, 1995) | | | | |
| *105 | Dieffenbach et al., <u>PCR Primer: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press (1995) | | | | |
| *106 | Dzau et al., "Gene Therapy for Cardiovascular Disease." <u>Trends in Biotechnology</u> 11:205-210 (1993) | | | | |
| *107 | Edge et al., "Deglycosylation of glycoproteins by trifluoromethanesulfonic acid" <u>Analytical Biochemistry</u> 118:131-137 (1981) | | | | |
| *108 | Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular & Cellular Biology</u> 5:3610-3616 (1985) | | | | |
| *109 | Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from Saccharomyces cerevisiae by Use of an Epitope Addition Method" <u>Molecular & Cellular Biology</u> 8:2159-2165 (1988) | | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | |
|---|--|---|--|-------------------------------|--------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1134R2C4 | Serial No. 10/688,132 |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Ashkenazi et al. | |
| | | | | Filing Date 17 Oct 2003 | Group |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| *110 | Gelb et al., "Pycnodysostosis: Refined Linkage and Radiation Hybrid Analyses Reduce the Critical Region to 2 cM at 1q21 and Map Two Candidate Genes" <u>Human Genet.</u> 98:141-144 (1996) | | | | |
| *111 | Gelmini et al., "Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification" <u>Clinical Chemistry</u> 43(5):752-758 (May 1997) | | | | |
| *112 | Gething and Sambrook, "Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene" <u>Nature</u> 293:620-625 (October 22, 1981) | | | | |
| *113 | Goding, "Production of Monoclonal Antibodies" <u>Monoclonal Antibodies: Principles and Practice</u> , Academic Press, pps. 59-103 (1986) | | | | |
| *114 | Goeddel et al., "Direct Expression in Escherichia coli of a DNA Sequence Coding for Human Growth Hormone" <u>Nature</u> 281:544-548 (October 18, 1979) | | | | |
| *115 | Goeddel et al., "Synthesis of Human Fibroblast Interferon by E. coli" <u>Nucleic Acids Research</u> 8(18):4057-4074 (1980) | | | | |
| *116 | Goodwin et al., "Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor." <u>Mol. Cell. Bio.</u> 11:3020-3026 (1991) | | | | |
| *117 | Graham and van der Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" <u>Virology</u> 52:456-467 (1973) | | | | |
| *118 | Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <u>J. Gen. Virol.</u> 36:59-72 (1977) | | | | |
| *119 | Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995) | | | | |
| *120 | Hahne et al., "Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape" <u>Science</u> 274(5291):1363-1366 (Nov 22, 1996) | | | | |
| *121 | Hale et al., "Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in E. coli." <u>J. Cell. Biochem.</u> (abstract only, suppl. 15F; P 424) pps. 113 (1991) | | | | |
| *122 | <u>Handbook of Monoclonal Antibodies</u> , Ferrone et al. eds., Park Ridge, NJ: Noyes Publications, pps. 302-359 and Chapter 22 (1985) | | | | |
| *123 | Hess et al., "Cooperation of Glycolytic Enzymes" <u>Advances in Enzyme Regulation</u> , George Weber, New York: Pergamon Press Vol. 7:149-167 (1968) | | | | |
| *124 | Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique" <u>Journal of Biological Chemistry</u> 255(24):12073-12080 (December 25, 1980) | | | | |
| *125 | Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF α)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989) | | | | |
| *126 | Holland and Holland, "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase" <u>Biochemistry</u> 17(23):4900-4907 (1978) | | | | |
| *127 | Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (1991) | | | | |
| *128 | Hoogenboom and Winter, "By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline V _H Gene Segments Rearranged in Vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992) | | | | |
| *129 | Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <u>Bio/Technology</u> 6:1204-1210 (1988) | | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | |
|---|------|--|-----------------|-------------------------------|--------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1134R2C4 | Serial No. 10/688,132 |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Ashkenazi et al. | |
| | | | | Filing Date 17 Oct 2003 | Group |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| | *130 | Hsiao and Carbon, "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4 Gene" <u>Proc. Natl. Acad. Sci. USA</u> 76:3829-3833 (1979) | | | |
| | *131 | Hunter et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity" <u>Nature</u> 194:495-496 (1962) | | | |
| | *132 | Itoh et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis." <u>Cell</u> 66:233-243 (1991) | | | |
| | *133 | Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986) | | | |
| | *134 | Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse." <u>Nature</u> 321:522-525 (May 29, 1986) | | | |
| | *135 | Jones, E., "Proteinase Mutants of <i>Saccharomyces Cerevisiae</i> " <u>Genetics</u> 85(1):23-33 (1977) | | | |
| | *136 | Keown et al., "Methods for Introducing DNA into Mammalian Cells" <u>Methods in Enzymology</u> 185:527-537 (1990) | | | |
| | *137 | Kingsman et al., "Replication in <i>Saccharomyces Cerevisiae</i> of Plasmid pBR313 Carrying DNA from the Yeast <i>trp1</i> Region" <u>Gene</u> 7:141-152 (1979) | | | |
| | *138 | Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996) | | | |
| | *139 | Kohler and Milstein., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity." <u>Nature</u> 256:495-497 (August 7, 1975) | | | |
| | *140 | Kohno et al., "A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor." <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990) | | | |
| | *141 | Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984) | | | |
| | *142 | Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994) | | | |
| | *143 | Kwon et al., "Manipulation of T Cell Costimulatory and Inhibitory Signals for Immunotherapy of Prostate Cancer." <u>Proc. Natl. Acad. Sci. USA</u> 94(15):8099-8103 (Jul 22, 1997) | | | |
| | *144 | Lacey et al., "Osteoprotegerin Ligand is a Cytokine That Regulates Osteoclast Differentiation and Activation." <u>Cell</u> 93(2):165-176 (Apr 17, 1998) | | | |
| | *145 | Leach et al., "Enhancement of antitumor immunity by CTLA-4 blockade" <u>Science</u> 271(5256):1734-1736 (Mar 22, 1996) | | | |
| | *146 | Lewis et al., "Cloning and Expression of cDNAs for Two Distinct Murine Tumor Necrosis Factor Receptors Demonstrate One Receptor is Species Specific." <u>PNAS USA</u> 88:2830-2834 (1991) | | | |
| | *147 | Li et al., "Targeted Mutation of the DNA Methyltransferase Gene Results in Embryonic Lethality." <u>Cell</u> 69:915-926 (Jun 1992) | | | |
| | 148 | Locksley et al., "The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology" <u>Cell</u> 104:487-501 (Feb 23, 2001) | | | |
| | *149 | Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990) | | | |
| Examiner | | | Date Considered | | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | |
|---|---|---|--|-------------------------------|--------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1134R2C4 | Serial No. 10/688,132 |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Ashkenazi et al. | |
| | | | | Filing Date 17 Oct 2003 | Group |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| *150 | Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990) | | | | |
| *151 | Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990) | | | | |
| *152 | <u>Mammalian Cell Biotechnology: A Practical Approach</u> , M. Butler, ed., IRL Press (1991) | | | | |
| *153 | Mansour et al., "Disruption of the Proto-oncogene int-2 in Mouse Embryo-derived Stem Cells: a General Strategy for Targeting Mutations to Non-selectable Genes" <u>Nature</u> 336:348-352 (1988) | | | | |
| *154 | Mantel et al., "Rabbit β -globin mRNA Production in Mouse L Cells Transformed with Cloned Rabbit β -globin Chromosomal DNA" <u>Nature</u> 281:40-46 (September 6, 1979) | | | | |
| *155 | Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage" <u>J. Mol. Biol.</u> 222:581-597 (1991) | | | | |
| *156 | Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA." <u>Current Biology</u> 6(6):750-752 (1996) | | | | |
| *157 | Marsters et al., "Apo-3, A New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- κ B." <u>Curr. Biol.</u> 6(12):1669-1676 (1996) | | | | |
| *158 | Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor Receptor (TNFR) Family, Interacts with Members of the TNFR-Associated Factor Family and Activates the Transcription Factors NF- κ B and AP-1." <u>J. Bio. Chem.</u> 272(22):14029-14032 (1997) | | | | |
| *159 | Marsters et al., "Identification of a Ligand for the Death-Domain-Containing Receptor Apo3." <u>Current Biology</u> 8(9):525-528 (1998) | | | | |
| *160 | Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K ⁺ Channel Currents" <u>Science</u> 255:192-194 (1992) | | | | |
| *161 | Mather, J.P., "Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines" <u>Biol. Reprod.</u> 23:243-252 (1980) | | | | |
| *162 | Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator" <u>Immunity</u> 8(1):21-30 (Jan 1998) | | | | |
| *163 | Medvedev et al., "Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas- ligand in NK/LAK cell-mediated cytotoxicity" <u>Cytokine</u> 9(6):394-404 (Jun 1997) | | | | |
| *164 | Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" <u>J. Am. Chem. Soc.</u> 85(14):2149-2154 (Jul 1963) | | | | |
| *165 | Milstein and Cuello, "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (Oct 1983) | | | | |
| *166 | Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996) | | | | |
| *167 | Moretta, A., "Molecular mechanisms in cell-mediated cytotoxicity" <u>Cell</u> 90(1):13-18 (Jul 11, 1997) | | | | |
| *168 | Munson and Rodbard, "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980) | | | | |
| *169 | Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995) | | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | |
|---|------|--|-----------------|-------------------------------|--------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1134R2C4 | Serial No. 10/688,132 |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Ashkenazi et al. | |
| | | | | Filing Date 17 Oct 2003 | Group |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| | *170 | Nagata, S., "Apoptosis by Death Factor." <u>Cell</u> 88:355-365 (Feb 1997) | | | |
| | *171 | Nophar et al., "Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes Both the Cell Surface and a Soluble Form of the Receptor." <u>EMBO Journal</u> 9:3269-3278 (1990) | | | |
| | *172 | Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982) | | | |
| | *173 | O'Reilly, D. <u>Baculovirus expression vectors: a laboratory manual</u> , New York:Oxford University Press (1994) | | | |
| | *174 | Otsuki et al., "Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients" <u>Clin. Exp. Immunol.</u> 119:323-327 (2000) | | | |
| | *175 | Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" <u>Protein Eng.</u> 3(6):547-553 (1990) | | | |
| | *176 | Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" <u>Journal of Immunological Methods</u> 40:219-230 (1981) | | | |
| | *177 | Pan et al., "An Antagonist Decoy Receptor and a Death-Domain Containing Receptor for TRAIL." <u>Science</u> 277:815-818 (Aug 1997) | | | |
| | *178 | Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL." <u>Science</u> 276:111-113 (Apr 4, 1997) | | | |
| | *179 | Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>European Journal of Haematology</u> 41:414-419 (1988) | | | |
| | *180 | Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" <u>Nature</u> 312:724-729 (1984) | | | |
| | *181 | Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996) | | | |
| | *182 | Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992) | | | |
| | *183 | Radeke et al., "Gene Transfer and Molecular Cloning of the Rat Nerve Growth Factor Receptor." <u>Nature</u> 325:593-597 (1987) | | | |
| | *184 | <u>Remington's Pharmaceutical Sciences</u> , Oslo et al., eds., 16th edition, Mack Publishing Co. (1980) | | | |
| | *185 | Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988) | | | |
| | *186 | Ruppert et al., "Cloning and Expression of Human TAF _{II} 250: a TBP-associated Factor Implicated in Cell-cycle Regulation" <u>Nature</u> 362:175-179 (1993) | | | |
| | *187 | Sambrook et al. <u>Molecular Cloning: A Laboratory Manual</u> , Second edition, New York: Cold Spring Harbor Laboratory Press (1989) | | | |
| | *188 | Samter et al. <u>Samter's Immunological Diseases</u> , 5th edition, Boston: Little, Brown and Company Vol. I & II (1995) | | | |
| | *189 | Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990) | | | |
| Examiner | | | Date Considered | | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | |
|---|--|---|--|-------------------------------|--------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1134R2C4 | Serial No. 10/688,132 |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Ashkenazi et al. | |
| | | | | Filing Date 17 Oct 2003 | Group |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| *190 | Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruct. Mediated by Cytotoxic T-cell Lines, Lymphotoxin-Secreting Helper T-cell Clones, and Cell-Free Lymphotoxin-Containing Supernatant." <u>PNAS USA</u> 83:1881-1885 (1986) | | | | |
| *191 | Scopes, R. <u>Protein Purification</u> , New York: Springer-Verlag (1982) | | | | |
| *192 | Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor α Inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989) | | | | |
| *193 | Shaw et al., "A General Method for the Transfer of Cloned Genes to Plant Cells" <u>Gene</u> 23:315-330 (1983) | | | | |
| *194 | Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997) | | | | |
| *195 | Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997) | | | | |
| *196 | Skinner et al., "Use of the Glu-Glu-Phe C-Terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins." <u>J. Bio. Chem.</u> 266:14163-14166 (1991) | | | | |
| *197 | Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990) | | | | |
| *198 | Smith et al., "Cardiac Glycoside-Specific Antibodies in the Treatment of Digitalis Intoxication" <u>Antibodies in Human Diagnosis and Therapy</u> pps. 365-389 (1977) | | | | |
| *199 | Smith et al., "T2 Open Reading Frame From the Shope Fibroma Virus Encodes a Soluble Form of the TNF Receptor." <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991) | | | | |
| *200 | Sojar et al., "A Chemical Method for the Deglycosylation of Proteins" <u>Archives of Biochemistry & Biophysics</u> 259(1):52-57 (1987) | | | | |
| *201 | Sompayrac et al., "Efficient infection of monkey cells with DNA of simian virus 40" <u>Proc. Natl. Acad. Sci. USA</u> 78(12):7575-7578 (Dec 1981) | | | | |
| *202 | Stamenkovic et al., "A B-Lymphocyte Activation Molecule Related to the Nerve Growth Factor Receptor and Induced by Cytokines in Carcinomas." <u>EMBO Journal</u> 8(5):1403-1410 (1989) | | | | |
| *203 | Stewart et al. <u>Solid-Phase Peptide Synthesis</u> , San Francisco, CA: W.H. Freeman Co. (1969) | | | | |
| *204 | Stinchcomb et al., "Isolation and Characterisation of a Yeast Chromosomal Replicator" <u>Nature</u> 282:39-43 (November 1, 1979) | | | | |
| *205 | Strand et al., "Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells -- a mechanism of immune evasion?" <u>Nature Medicine</u> 2(12):1361-1366 (Dec 1996) | | | | |
| *206 | Suda et al., "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family" <u>Cell</u> 75:1169-1178 (1993) | | | | |
| *207 | Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986) | | | | |
| *208 | Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993) | | | | |
| *209 | Thimmappaya et al., "Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection" <u>Cell</u> 31(3 Pt 2):543-551 (Dec 1982) | | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | |
|---|------|--|-----------------|-------------------------------|--------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1134R2C4 | Serial No. 10/688,132 |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Ashkenazi et al. | |
| | | | | Filing Date 17 Oct 2003 | Group |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| | *210 | Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells." <u>Cell</u> 51:503-512 (Nov 1987) | | | |
| | *211 | Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5201-5205 (September 1980) | | | |
| | *212 | Thotakura and Bahl, "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> 138:350-359 (1987) | | | |
| | *213 | Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" <u>EMBO Journal</u> 10(12):3655-3659 (1991) | | | |
| | *214 | Tschumper and Carbon, "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene" <u>Gene</u> 10:157-166 (1980) | | | |
| | *215 | Upton et al., "Myxoma Virus Expresses a Secreted Protein with Homology to the Tumor Necrosis Factor Receptor Gene Family that Contributes to Viral Virulence." <u>Virology</u> 184:370-382 (1991) | | | |
| | *216 | Upton et al., "Tumorigenic Poxviruses: Genomic Organization and DNA Sequence of the Telomeric Region of the Shope Fibroma Virus Genome." <u>Virology</u> 160:20-30 (1987) | | | |
| | *217 | Urlaub and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> 77(7):4216-4220 (July 1980) | | | |
| | *218 | Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> 130:946-947 (1977) | | | |
| | *219 | Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988) | | | |
| | *220 | Wagner et al., "Transferrin-Polycation Conjugates as Carriers for DNA Uptake Into Cells." <u>Proc. Natl. Acad. Sci.</u> 87:3410-3414 (May 1990) | | | |
| | 221 | Wallach, "TNF Ligand and TNF/NGF Receptor Families" <u>Cytokine Reference</u> , Academic Press pps. 377-411 (2000) | | | |
| | *222 | Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991) | | | |
| | *223 | Wells et al., "Cassette Mutagenesis: An Efficient Method for Generation of Multiple Mutations at Defined Sites" <u>Gene</u> 34(2-3):315-323 (1985) | | | |
| | *224 | Wells, J. et al., "Importance of Hydrogen-Bond Formation in Stabilizing the Transition State of Subtilisin" <u>Philos. Trans. Royal Soc. London Ser. A</u> 317:415-423 (1986) | | | |
| | *225 | Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995) | | | |
| | *226 | Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells." <u>J. Bio. Chem.</u> 272(40):25190-25194 (Oct 3, 1997) | | | |
| | *227 | Wu, G.Y. and C. H. Wu., "Receptor-Mediated in Vitro Gene Transformation by a Soluble DNA Carrier System." <u>J. Bio. Chem.</u> 262(10):4429-4432 (Apr 1987) | | | |
| | *228 | Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" <u>Journal of Biological Chemistry</u> 266:12099-12104 (1991) | | | |
| | *229 | Yonehara et al., "A Cell-Killing Monoclonal Antibody (Anti-Fas) to a Cell Surface Antigen Co-Downregulated with the Receptor of Tumor Necrosis Factor." <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989) | | | |
| Examiner | | | Date Considered | | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

